Norfenefrine
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
4
Phase 4
0
Earliest trial started May 1, 2008 (NCT00721695)
Timeline
Indications
Mechanism of action
Alpha adrenergic receptor (1a and 1d) agonist
Chemistry & pharmacology
Loading structure…
SMILES
NCC(O)c1cccc(O)c1- Mol. weight
- 153.18 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL358040 ↗
Also known as
- dl-norphenylephrine
- metacardiol
- metaoctopamine
- norfenefrine
- norfenefrine
- norfenefrine
- norfenefrine
- norfenefrine
- norfenefrine hcl
- norfenefrine hydrochloride
- normetasympathol
- normetasynephrine
- normezaton
- norphenephrine
- norphenylephrine
- oms302
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02132312 | Phase 3 | Jul 1, 2014 | Omeros Corporation |
| NCT02093689 | Phase 3 | Feb 1, 2014 | Omeros Corporation |
| NCT01579565 | Phase 3 | Apr 1, 2012 | Omeros Corporation |
| NCT01454063 | Phase 3 | Sep 1, 2011 | Omeros Corporation |
| NCT01193127 | Phase 2 | Jul 1, 2010 | Omeros Corporation |
| NCT00721695 | Phase 1/Phase 2 (Phase 2) | May 1, 2008 | Omeros Corporation |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Omeros Corporation | For profit | 6 | 6 | 2 | 2008 |
1 organizations
Page 1 / 1